Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to BioNTech SE (BNTX – Research Report). The ...

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

COVID-19 vaccines were not associated with increased risk for thyroid diseases but were associated with increased risk for exacerbated hypothyroidism.

BioNTech SE trades -13.2% away from its average analyst target price of $136.12 per share. The 20 analysts following the ...

Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which ...

Truist Financial initiated coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a research report released on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a ...

Around 5,000 workers walked off the job at Providence hospitals Friday, demanding better pay and working conditions.

BioNTech SE ADR closed $8.64 short of its 52-week high ($131.49), which the company achieved on September 17th.

Truist rates BioNTech a Buy, citing its shift to oncology with BNT327 leading the way. Key data updates and growth catalysts ...